EW vs IDXX

Edwards Lifesciences (EW) trades near its 52-week high at $86.30, reflecting strong recent price momentum (+30.4% 1Y, +18.3% 1M), supported by consistent revenue growth of 14.7% YoY and a solid track record of earnings beats over the past four quarters (avg. surprise: 9.24%). The company exhibits best-in-class profitability with a 78.2% gross margin and 27.4% operating margin, significantly above sector averages, while maintaining a fortress balance sheet with a Debt/Equity ratio of just 0.07 and a Current Ratio of 4.0. However, near-term earnings growth is deeply negative (-90.3% YoY), creating a dislocation between top-line strength and bottom-line performance, and insider selling worth $4.7M over the last six months raises caution. While analysts maintain a 'buy' recommendation with a $93.94 target implying 8.9% upside, valuation appears stretched relative to growth, particularly when compared to higher-growth peers like BNTX or capital-efficient leaders like ZTS.

IDEXX Laboratories trades at a premium valuation with a P/E of 54.63 and forward P/E of 57.69, reflecting its elite profitability and consistent earnings outperformance. The company has delivered 21 of the last 25 quarters with positive EPS surprises, including a 10% beat in the most recent quarter, underpinning strong execution and demand tailwinds in the veterinary diagnostics space. Despite insider selling activity totaling $40.92M over the past six months, the robust growth trajectory, sector-leading ROE of 64.63%, and favorable peer context—especially against lower-growth but cheaper names like ZTS—support continued outperformance. Price momentum remains strong, with a 1Y return of +62.9%, significantly outpacing the healthcare sector average and validating market confidence in sustained earnings growth.